<DOC>
	<DOCNO>NCT00403910</DOCNO>
	<brief_summary>The RALES study show spironolactone reduces risk morbidity mortality progressive heart failure sudden death , patient NYHA III IV heart failure . This favourable effect clearly independent diuretic effect . Antialdosterone drug may effective opposes effect aldosterone sodium retention , loss magnesium potassium , sympathetic activation , baroreceptor function vascular compliance . Antialdosterone treatment may also antagonize effect aldosterone promote cardiac fibrosis . In RALES substudy baseline serum PIIINP , marker cardiac fibrosis synthesis show independent negative correlation survival CHF hospitalization placebo group . Therefore seem interesting evaluate effect Aldosterone receptor blocker progression leave ventricular dysfunction patient mild heart failure assume standard therapy .</brief_summary>
	<brief_title>Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure . AREA IN-CHF Study</brief_title>
	<detailed_description>The protocol sponsor independent organization partially support Therabel</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Canrenone</mesh_term>
	<criteria>Established diagnosis congestive heart failure NYHA class II Left ventricular ejection fraction &lt; = 45 % measure within 6 month enrolment Stable standard heart failure therapy ( patient beta blocker drug , treatment must start least three month enrolment ) Informed consent ( obtain prior study procedure ) Age &lt; 18 &gt; 80 Serum creatinine level &gt; 2.5 mg per deciliter Serum potassium level &gt; 5.0 mmol per liter Valvular heart disease amenable surgical treatment Congenital heart disease Unstable angina and/or acute myocardial infarction and/or coronary revascularization procedure within three month enrolment Intravenous therapy inotropic drug within three month enrolment History resuscitate ventricular fibrillation tachycardia , unless occur within 24 hour acute myocardial infarction subject implant automatic cardioverter defibrillator Chronic active hepatitis cirrhosis Malignant neoplasm life threaten non cardiac disease History hypersensitivity study drug Pregnancy lactate childbearing age woman protect accepted method contraception History drug alcohol abuse Legal incapacity and/or circumstance rend patient unable understand nature , scope possible consequence study . Evidence uncooperative attitude Any condition heart failure permit optimal participation trial Participation RCTs last 3 month Treatment : Lithium salt , Potassium spar diuretic , oral positive inotropic drug investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>